CrosswordNewsletters
DAILY BEAST
ALL
  • Cheat Sheet
  • Politics
  • Crime
  • Entertainment
  • Media
  • Innovation
  • Opinion
  • World
  • U.S. News
  • Scouted
  • Travel
CHEAT SHEET
    POLITICS
    • Biden World
    • Elections
    • Opinion
    • National Security
    • Congress
    • Pay Dirt
    • The New Abnormal
    • Right Richter
    • Trumpland
    MEDIA
    • Daytime Talk
    • Late-Night
    • Fox News
    U.S. NEWS
    • Identities
    • Crime
    • Race
    • LGBT
    • Extremism
    • Coronavirus
    WORLD
    • Russia
    • Europe
    • China
    • Middle East
    SCIENCE
    • Hunt for the Cure
    • Rabbit Hole
    TRAVEL
      ENTERTAINMENT
      • TV
      • Movies
      • Music
      • Comedy
      • Sports
      • Sex
      • TDBs Obsessed
      • Awards Shows
      • The Last Laugh
      HALF-FULL
        CULTURE
        • Power Trip
        • Fashion
        • Books
        • Royalist
        TECH
        • Disinformation
        SCOUTED
        • Face Masks
        • Clothing
        • Technology
        • Bedroom
        • Kitchen
        • Home
        • Fitness
        • The Case For
        • I'm Looking For
        • New Kids On the Block
        COUPONS
        • Adidas Promo Codes
        • DoorDash Promo Codes
        • H&M Coupons
        • Hotwire Promo Codes
        • Wine.com Discounts
        • Vitacost Coupons
        • Spanx Promo Codes
        • StubHub Promo Codes
        Products
        NewslettersPodcastsCrosswordsSubscription
        FOLLOW US
        GOT A TIP?

        SEARCH

        HOMEPAGE

        Searching for Miracles

        We get too little from medical innovation because we expect too much.

        Megan McArdle

        Updated Apr. 21, 2017 2:13PM ET / Published Dec. 10, 2012 11:17AM ET 

        The New York Times reports on a remarkable trial of a new gene-based therapy for leukemia, which reprograms the patient's own immune system to fight the rogue cells. The results have been nothing short of remarkable:

        Three adults with chronic leukemia treated at the University of Pennsylvania have also had complete remissions, with no signs of disease; two of them have been well for more than two years, said Dr. David Porter. Four adults improved but did not have full remissions, and one was treated too recently to evaluate. A child improved and then relapsed. In two adults, the treatment did not work at all. The Pennsylvania researchers were presenting their results on Sunday and Monday in Atlanta at a meeting of the American Society of Hematology.

        "Despite the mixed results," the story goes on, "cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.

        "Mixed results?" These are fantastic results. Twelve people were treated for end-stage, multi-drug resistant leukemia; one third are in full remission. More than one third have at least slowed the progress of their disease. These are people who had one foot, and the toes on the other foot, in the grave. Even if this is only a temporary respite, it's a major success.

        It strikes me that medical research is haunted by the memory of penicillin, and the other antibiotics that immediately followed. For a period of ten or fifteen years, "miracle cures" were the stuff of everyday life rather than television movies and late night infomercials: you took a pill, and something that had previously been fatal, like pneumonia or tuberculosis, simply went away. Often, you went from death's door to the picture of health in hours or days.

        As a consequence, people think that this is how medical discoveries are supposed to work: you find a cure for a fatal or crippling disease, everyone gets better instantly, and the world is a better place. I suspect that this is Big Pharma critic Marcia Angell's mental model. The reason she's decided that drug companies are about as useful as a third buttock is that they're no longer delivering the miracle pills on schedule.

        But this is not how innovation works most of the time. Innovation is not "Problem solved forever!" Instead it's mostly "We've reduced the incidence of this problem by 11.3%." But if you do that over and over again, eventually you can produce a pretty good fascimile of the miracle cure you thought you were supposed to get in the first place.

        Unfortunately, Penicillin Envy can make it difficult to achieve those lesser innovations. A while back, Michael Mandel pointed out that the FDA frequently makes the perfect the enemy of the "needs improvement"--and thereby kills promising technologies. A company that developed a computer system for diagnosing melanoma was turned down on the grounds that it didn't do as good a job as the best dermatologists. Of course, not everyone has access to the best dermatologists--and more importantly, there's no reason to think that the first-generation system will do as good a job as the eighth generation. But if you kill the first generation, you also kill the eighth.

        The FDA eventually reversed itself, but the mentality remains. We expect to many miracle cures, and as a result, we get fewer medical miracles.

        READ THIS LIST

        DAILY BEAST
        • Podcasts
        • Cheat Sheet
        • Politics
        • Crime
        • Entertainment
        • Media
        • Covid-19
        • Half Full
        • U.S. News
        • Scouted
        • Travel
        • Subscription
        • Crossword
        • Newsletters
        • Podcasts
        • About
        • Contact
        • Tips
        • Jobs
        • Advertise
        • Help
        • Privacy
        • Code of Ethics & Standards
        • Diversity
        • Terms & Conditions
        • Copyright & Trademark
        • Sitemap
        • Coupons
        © 2022 The Daily Beast Company LLC